Table 2.
The final AQUILA checklist for use by authors
| Reportinbg Quality Item |
|---|
| 1. Are the inclusion and exclusion criteria clearly reported? |
| 2. Is information regarding the number of patients who did not gave informed consent and who were not willing to participate adequately reported? |
| 3. Are the baseline characteristics of included patients reported? |
| 4. Is the surgical technique adequately reported? |
| 5. Are the prosthesis brand and fixation reported with enough detail? |
| 6. Are the reasons or definitions for revision adequately reported? |
| 7. Are the number of revisions (N) and revision rates regarding aseptic loosening (either Kaplan-Meier or life table or revisions per 100 observed component years) adequately reported? |
| 8. Is the number of deaths, lost-to-follow up (e.g. no show at clinic or emigration), amputations, and revisions other than the primary endpoint adequately reported? |
| Methodological Quality Item |
| 1. Is there a clear primary research question/hypothesis?* |
| 2. How were the cohorts constructed? |
| a. Consecutivelya |
| b. Non-consecutively |
| c. Unknown |
| 3. How adequate was the follow-up (FU)? |
| a. Fully completed FU |
| b. 5% or less lost-to-FU or FU quotientb is 1 or less |
| c. More than 5% lost-to-FU or FU quotient is more than 1 |
| d. Unknown |
| 4. How was the FU performed? |
| a. Predefined e.g. yearly |
| b. When patients had complaints or chart review (of non-predefined FU) |
| c. Unknown |
| 5. How many arthroplasties are at risk at the FU of interest? |
| a. 20 or more |
| b. Less than 20 |
| b. Unknown |
| 6. Has a worst case analysis or competing risk analysis for competing endpoints [14] been performed? |
* In cases of aseptic loosening: Does the research question or hypothesis include revision of the component due to aseptic loosening?
a Consecutively is defined as all patients receiving an arthroplasty (TKA or THA) in a defined period of time have also received the arthroplasty of interest. The following situation is therefore non-consecutive: patients receiving prosthesis X while prosthesis Y has also been used for the same indication during the specified period.
b FU quotient = Number lost to follow up/Number of failures [26].